Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
09 août 2013 16h23 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
Inform Genomics Presents Biologic Validity for OnPART Predictive Networks Identifying Potential Genomic Targets for Drug Discovery
03 juin 2013 08h00 HE
|
Inform Genomics
Boston, MA, June 3, 2013 (GLOBE NEWSWIRE) -- Inform
Genomics, Inc., a private company focused on developing novel
platforms of genomic-based personalized medicine products for
cancer supportive...
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
04 févr. 2013 19h35 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and...
FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
14 août 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
01 août 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
18 juil. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment
11 juil. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...
Chronix Biomedical and Hemispherx Biopharma Jointly File Patent Application for a Blood Test for Chronic Fatigue Syndrome (CFS)
03 mars 2011 10h00 HE
|
Hemispherx Biopharma, Inc.
Chronix Technology Focuses on Changes to CFS Patients' DNA
Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS
SAN JOSE, Calif., March 3, 2011...